Attorneys In Pre-Emption Case Seek To Add Documents Indicating Two FDA Officials Objected To Rules Aimed At Pre-Empting Lawsuits

Main Category: Regulatory Affairs / Drug Approvals
Also Included In: Litigation / Medical Malpractice;  Pharma Industry / Biotech Industry
Article Date: 03 Nov 2008 - 0:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  

Current Article Ratings:

Patient / Public:5 stars

5 (1 votes)

Healthcare Prof:not yet rated


Plaintiff attorneys in Wyeth v. Levine, a U.S. Supreme Court case that could determine whether patients have the ability to file product liability lawsuits against pharmaceutical companies in state courts, on Thursday requested that the court add to the case record documents from FDA officials who expressed opposition to pre-emption, Dow Jones reports. Supporters of pre-emption, a legal principle under which federal laws supersede state laws, maintain that FDA approval of medication labels pre-empts the ability of consumers to file lawsuits against pharmaceutical companies under state product liability laws.

In 2006 and 2008, FDA issued rules that increased agency responsibility for medication labels in support of pre-emption. In addition, FDA has filed a friend-of-the-court brief in support of pre-emption in the case (Mundy, Dow Jones, 10/30).

However, according to internal documents released on Wednesday by House Oversight and Government Reform Committee Chair Henry Waxman (D-Calif.), two FDA officials objected to the rules. According to the documents, the two FDA officials in memos said that FDA approval of medication labels is not completely reliable or based on full disclosure of safety risks by pharmaceutical companies (Kaiser Daily Health Policy Report, 10/30).

Plaintiff attorney David Frederick on Thursday in the letter to the court wrote, "The internal communications of the FDA's expert staff undermine the factual bases of the contention that the Solicitor General and the petitioner Wyeth have made in their submissions in their case." Wyeth declined to comment on the issue (Dow Jones, 10/30).

Reprinted with kind permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation.

© 2008 Advisory Board Company and Kaiser Family Foundation.  All rights reserved.

Article adapted by Medical News Today from original press release.
Visit our regulatory affairs / drug approvals section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
Kaiser. "Attorneys In Pre-Emption Case Seek To Add Documents Indicating Two FDA Officials Objected To Rules Aimed At Pre-Empting Lawsuits." Medical News Today. MediLexicon, Intl., 3 Nov. 2008. Web.
14 Feb. 2012. <http://www.medicalnewstoday.com/releases/127802.php>

APA
Kaiser. (2008, November 3). "Attorneys In Pre-Emption Case Seek To Add Documents Indicating Two FDA Officials Objected To Rules Aimed At Pre-Empting Lawsuits." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/127802.php.

Please note: If no author information is provided, the source is cited instead.


Regulatory Affairs / Drug Approvals

Most Popular Articles



Follow Our Regulatory Affairs News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Regulatory Affairs / Drug Approvals Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »